RGEN News and Press, Repligen Corporation From 02/21/23

Repligen ( NASDAQ: RGEN ) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, before market open. The consensus EPS Estimate is $0.58 (-28.4% Y/Y) and the consensus Revenue Estimate is $184.41M (-1.1% Y/Y). Over the last 2 years, RGEN has beaten EPS est...

WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus. Dr. Madaus brings to the Repligen board over 25 years of industry experience, including five ...

WALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on Wednesday, February 22, 2023. The Company will issue a press release before the market opens and will host a...

Summary Despite our largest holding declining sharply during the month, gains elsewhere in the portfolio helped overall performance. I remain optimistic for the year ahead and our investment strategy. The apparent return of the meme-stock mania has led to somewhat of a short-squeeze...

Summary Charles River Laboratories has proven itself to be a quality player in its space. Shares of the company don't look all that cheap, but they aren't exactly expensive either. When paired with the consistency of its growth and the robust cash flows of the firm, it becomes a dec...

Shares of Repligen (NASDAQ: RGEN) were up 14.8% for the week late Thursday afternoon, according to S&P Global Market Intelligence . The healthcare company specializes in bioprocessing technology and creating solutions for the making of biologic drugs. It specializes in chr...

Summary iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. Healthcare and pharmaceutical shares have a strong track record of holding up during bear markets and recessions over the last 100 years. The Top 10 hold...

Summary The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights. This article will discuss the 10 largest biotech companies (by ma...

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 41st Annual J.P. Morgan Healthcare conference being held January 9-12 in San Francisco.&#x...

Summary A 3-5 month prospect from here of RGEN share prices could reasonably range from a $156.4 low to a $190.62 high from its present $162.42 price, a +17.4% gain. 88 positions like today’s in the past 5 years of 1261 market days resulted in 12.1% average net gains each during ...